Introduction
Gastric cancer (GC) is the fourth most common cancer and the second leading cause of cancer death worldwide, with an estimated 950,000 cases and 720,000 deaths per year.
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chen et al radio and surgical treatments, the 5-year overall survival rate remains poor. 3 Approximately 60% of GC patients are in an advanced stage and metastasis at initial diagnosis, resulting in a poor prognosis. 4 Moreover, several genes are identified in association with the development and progression of GC, but the mechanism remains unclear. 5 In recent years, with the development of high-throughput gene-detecting technology, many studies adopted microarrays to identify genes associated with GC progression. 6, 7 However, most studies ignored the high interconnection between genes are probably correlated in function although genes have similar expression patterns and only focused on the screening of differentially expressed genes. 8 Identification of GC prognostic biomarkers might be clinically important. A systems biology algorithm of weighted gene co-expression network analysis (WGCNA) has been used to evaluate the association between genes sets and clinical traits by constructing a scale-free gene co-expression network. [9] [10] [11] Thus, we applied the WGCNA algorithm to identify network-centric genes associated with the progression and prognosis of GC.
Materials and methods
Data collection
Microarray datasets were downloaded from the Gene Expression Omnibus (GEO) database (http://www.ncbi. nlm.nih.gov/geo/) and performed on Affymetrix Human Genome U133 Plus 2.0 Array platform (GPL570). Dataset GSE34942 12 was used as a training set to construct co-expression networks and identify hub genes in this study. This dataset included 56 samples of primary GC with different Lauren type and TNM stages. Two samples with no clinical data (GSM858086 and GSM858122) were removed from the subsequent analyses. Another dataset of GSE13911 13 was used as a testing set to verify our results. This dataset included 31 adjacent normal tissues and 38 GC tissues. Meanwhile, RNA-sequencing data of 367 GC samples and relevant clinical data were downloaded from database of The Cancer Genome Atlas (TCGA) (http:// genome-cancer.ucsc.edu/) to further validate our results. The detailed clinical data of training set and testing set are shown in Table S1 .
Data preprocessing
Raw microarray data were calculated by robust multiarray average (RMA) background correction and log 2 transformed and normalized by quantile normalization. Then, median-polish probesets was used in the "affy" R package to summarize. At last, we annotated probes by the Affymetrix annotation files. Microarray quality was evaluated by sample clustering association with Pearson's correlation matrices between different samples. Then, we chose a height of 0.2 as the cutoff criteria to identify potential microarray outliers. We filtered probes by their variances, and probes with variances ranked in top 10,000 were used for WGCNA. 14 co-expression network construction WGCNA package in R was used to construct co-expression network for the filtered genes in GSE34942. 8, 15 First, Pearson's correlation matrices were calculated between pairwise genes. Then, a weighted adjacency matrix was performed by a power function a m =|c mn | ® (c mn =Pearson's correlation between gene m and gene n; a mn =adjacency between gene m and gene n). The soft threshold power β could emphasize penalize weak correlations and strong correlations between genes. 16, 17 Next, the adjacencies were transformed into topological overlap matrix (TOM). 18 Then, in order to classify genes with similar expression profiles into modules, average linkage hierarchical clustering was performed by the TOM-based dissimilarity with a minimum module size of 30 for the genes dendrogram. 11 At last, the dissimilarity of module eigengenes (MES) was calculated for module dendrogram and some modules were merged.
Identification of clinical significant modules and functional annotation
Two approaches were applied to identify association of modules with clinical traits. Gene significance (GS) was defined as correlation between the genes and clinical data, and the average GS for all the genes in a module was defined as module significance (MS). Additionally, the major component analysis for each gene module was defined as MES and the expression patterns of genes could be generalized into a single characteristic expression profile within a given module. After calculating the association with GS and MES, the module with the mostly absolute MS among all the selected modules was defined as the one related to clinical trait. To further analyze the potential function of module genes, DAVID (http://david.abcc.ncifcrf.gov/) database was used along with gene GO functional enrichment analysis. False discovery rate (FDR) 0.01 was set as the cutoff criteria.
Identification of hub genes
Hub genes comprise highly interconnected nodes within a module and have been shown to be functionally significant. 19 OncoTargets and Therapy 2018:11 submit your manuscript | www.dovepress.com
Dovepress
6427
Co-expression network analysis identified CDH11
In this study, we chose a significant module, and hub genes were considered with highly module membership (MM) measured by Pearson's correlation (correlation. weighted 0.8) 20, 21 Also, hub genes in the module showed the highest correlation with the clinical trait. Furthermore, the significant module was constructed using the protein-protein interaction (PPI) network with a combined score of 0.4, which was regarded as a positive interaction between genes based on the STRING database (http://www.string-db.org/). 22 A connectivity degree of 10 was also defined as a hub gene. We regarded the common hub genes in the co-expression network and PPI network as "real" hub genes for further analysis.
hub gene validation
Gene Expression Profiling Interactive Analysis (GEPIA) database (http://gepia.cancer-pku.cn) was used to validate the correlation between the expression levels of hub genes and the stages. We also used the testing set of GSE13911 and Oncomine database (http://www.oncomine.org) to check the expression values of the hub gene in normal gastric tissues and GC tissues. Then, the Human Protein Atlas (http://www. proteinatlas.org) was used for immunohistochemistry validation. In addition, Kaplan-Meier plotter (http://www.kmplot. com) was used to estimate the prognosis including 1,065 GC patients. The GC patients were divided into two groups according to the expression of a particular gene (high vs low expression). The testing set of RNA-sequencing data including 367 GC samples was also applied for survival analyses. The survival curve was generated by log-rank estimator, and the association between hub gene and survival was calculated using the Cox proportional hazards regression model. Difference with statistical significance was defined as P0.05.
gene set enrichment analysis (gsea)
In all, 367 GC samples from RNA-sequencing data were divided into two groups according to the median values of the expression of hub genes (high vs low expression). GSEA was performed using the two groups to identify potential function of the hub gene 23 and chose the annotated gene sets of c2.cp.kegg.v5.2.symbols.gmt as the reference gene sets. Differences at nominal P0.05, FDR 0.05 and enrichment score (ES) 0.6 were defined as the cutoff criteria.
Results
Data preprocessing
After data preprocessing, the 54 GC samples in the training set GSE34942 were obtained. According to the outlier detection, no samples were removed in the training set ( Figure S1 ). Under the threshold of variance, we selected probes with the variances ranked in top 10,000 for subsequent analysis.
Weighted co-expression network construction and identification of key modules
In all, 54 GC samples with complete clinical data were used for co-expression analysis. We used WGCNA package on R to put probes with variances ranked in top 10,000 into modules by average linkage clustering ( Figure  1A ). In this study, we selected the power of β=9 (scale-free R 2 =0.89) as the soft thresholding to ensure a scale-free network ( Figure 1B and C). A total of 11 modules were identified ( Figure 2A ). The relevance between module and clinical traits was tested using two methods. First, we found the highest MES between the purple module and TNM stage ( Figure 2B ). Afterward, the purple module also had the highest MS in relation to the TNM stage (Figure 2C) . Thus, we identified that the purple module was the most relevant to the TNM stage in the training set.
To get a primary understanding of the biological relevance of purple module, 185 genes of purple module were enriched by using DAVID database for GO functional enrichment analysis. Top 20 biological processes enriched in GO terms ( Figure 2D ). The genes in the purple module mainly enriched in "vasculature development", "biological adhesion", "extracellular structure organization", "multicellular organismal macromolecule metabolic process", "multicellular organism metabolic process" and "skeletal system development".
Identification of hub genes for TNM stage in the purple module
Highly interconnected hub genes within a module have been shown to have important roles in the biological processes. 24 Therefore, 12 genes associated with the high connectivity in the purple module (correlate.weighted 0.8) were identified as hub genes (Table 1) . Based on the STRING database, a PPI network for all genes in the purple module was constructed using Cytoscape ( Figure S2 ). We identified genes with a connectivity degree of 10 as hub genes in the PPI network. Finally, CDH11, MMP2, LUM, FNB1, VCAN and COL8A1 in both co-expression network and PPI network were defined as "real" hub genes (Table 1) .
hub gene validation
In the training set, GSE34942 was used for linear regression analyses to validate hub genes. CDH11 was found to have a higher correlation with the TNM stage (R 2 =0.852) and was strongly correlated with biological adhesion based on GO functional enrichment analysis. Furthermore, expression of CDH11 in the diffuse-type GC was higher than that in the intestinal-type GC ( Figure 3C ). Thus, CDH11 was taken as the candidate gene for further validation. Based on the GEPIA dataset, we validated that CDH11 expression had a strong positive correlation with GC stages (P0.0001; Figure 3A ). In the testing set GSE13911 and Oncomine dataset, CDH11 was more highly expressed in GC tissues than in normal tissues (P0.0001; Figure 3B and D).
Then, immunohistochemistry staining validated from the Human Protein Atlas database revealed that CDH11 protein was significantly higher in GC tissues compared with normal gastric tissues ( Figure 3E ). As the tumor progression always affected the tumor prognosis, we performed a further validation of CDH11. Based on the testing set of RNA-sequencing data, a higher expression of CDH11 in GC patients showed a significantly poorer overall survival time (HR: 1.448, 95% CI: 1.009-2.007, P=0.042; Figure 3F ). More convincingly, Cox proportional hazards regression model performed using the RNA-sequencing data demonstrated that CDH11 
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Co-expression network analysis identified CDH11 expression was an independent predictor for overall survival time of GC (HR=1.482, 95% CI: 1.015-2.164, P=0.045; Table 2 ). In addition, survival analysis was conducted using the Kaplan-Meier plotter online tool, and a higher expression of CDH11 in GC patients also showed a poorer prognosis ( Figure 3G ).
gene set enrichment analysis
To characterize the potential mechanisms of CDH11 in association with GC, GSEA was applied to obtain biological process enriched in CDH11 with highly expressed samples. Then, 20 functional gene sets were enriched, and six representative pathways were "regulation of actin cytoskeleton", 
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chen et al "focal adhesion", "pathways in cancer", "TGF-β signaling pathway", "ECM receptor interaction" and "MAPK signaling pathway" (Figure 4 and Table S2 ).
Discussion
CDH11 (also known as OB cadherin) is a member of the cadherin superfamily, a group of transmembrane proteins that principally mediated homophilic cell-to-cell adhesion. 25, 26 Mature cadherin proteins are composed of a large N-terminal extracellular domain, a single membrane-spanning domain and a small highly conserved C-terminal cytoplasmic domain. 27 In addition, Kalluri and Weinberg 28 reported that cell adhesion molecules were associated with epithelial to mesenchymal transition (EMT), which suggests that CDH11 plays a critical role in cancer progression. Furthermore, CDH11 expression was linked with many pathologic processes, such as inflammation and fibrosis, which played an important role in the progression from chronic inflammation to cancer. 23, 29 In addition, CDH11 has been implicated in prostate, breast and colorectal cancer metastases. [30] [31] [32] In this study, we identified and validated gene coexpression modules related to the progression of GC by WGCNA. In all, 12 hub genes were identified that were significantly correlated with the TNM stage of GC patients. The GO functional annotation of module genes that were enriched in system development, biological adhesion, extracellular structure organization and metabolic process. CDH11 was mostly highly correlated with TNM stage and strongly correlated with biological adhesion, and expression of CDH11 in diffuse-type GC was higher than that in intestinal-type GC. 
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Co-expression network analysis identified CDH11 Qiu et al 33 found that patients with diffuse-type GC progress faster and have 5-year survival rate poorer than those with intestinal-type GC. Thus, we speculated that CDH11 might affect the TNM stage and prognosis of GC patients.
However, very few studies have identified the role of CDH11 in GC. 34 In our study, CDH11 was positively correlated with GC stages based on the GEPIA dataset. Additionally, in the testing set GSE13911 and Oncomine dataset, we also found a significantly overexpression of CDH11 in GC tissues. We also used the Human Protein Atlas database to find that the CDH11 protein was significantly higher in GC tissues. Several investigators demonstrated that CD11 was a mesenchymal cadherin in association with more undifferentiated and aggressive cancers, such as pancreatic cancer, prostate cancer, breast cancer and colorectal cancer. [27] [28] [29] [30] As a result, the overexpression of CDH11 might be related to malignant nature of GC. As we know, TNM staging system has been used for prognostic prediction. Thus, genes related to TNM stage were supposed to be associated with the prognosis. Moreover, the prognostic value of CDH11 had been identified in prostate cancer, breast cancer, colorectal cancer, glioblastoma and osteosarcoma. [28] [29] [30] 35, 36 However, no evidence revealing the role of overexpression of CDH11 related to the prognosis of GC. In our study, we performed survival analysis to validate the role of CDH11 in GC prognosis, and the highly expressed CDH11 was related to a shorter overall survival time. Furthermore, Cox regression analysis was performed on the RNA-sequencing data and demonstrated that CDH11 expression was an independent predictor for the prognosis of GC. Thus, the expression of CDH11 might be positively correlated with the progression and prognosis in GC.
As for the functional annotation, CDH11 was strongly correlated with biological adhesion, and we conducted GSEA analysis to reveal that CDH11 with highly expressed samples was enriched in regulation of focal adhesion, which was closely related to cancer development. 37, 38 Focal adhesion consists of cell-extracellular components, actin cytoskeleton and integrin. 39 It was reported that focal adhesion was significantly associated with multiple biological processes, such as cell proliferation, cell differentiation and cell survival. 40 Tomkiewicz et al 41 reported a novel cell-migratory program that the AhR through the activation of Src activates FAK and promotes integrin clustering and the activation of the AhR increases the interaction of FAK with the metastatic marker, HEF1/NEDD9/CAS-L and the expression of several integrins. McAndrews et al 42 elucidated that CDH11 promoted breast, ovarian and prostate cancer cell growth, survival and invasion by targeting cell adhesion molecules and blockade of CDH11 on stromal cells inhibited adhesion. According to our results, we could speculate that the overexpressed CDH11 might lead to cancer cell growth, migration and invasion of GC by regulating focal adhesion pathway. In addition, the expression of CDH11 may be positively associated with the degree of malignancy and prognosis of GC.
Some limitations of our study should be mentioned. First, this was a retrospective design study rather than a prospective cohort study. In addition, a large number of samples are required to validate our finding.
Conclusion
Our study adopted systems biology-based WGCNA method to identify and validate network hub genes in association with the GC clinical traits. Finally, CDH11 was identified and validated in association with progression and prognosis in GC, probably, by regulating biological adhesion and focal adhesion-related pathways. -349  M1  -18  n  n0  117  n1  -102  n2  -79  n3  -69  T  T1  -20  T2  -77  T3  -172  T4  -98  TNM stage  i  11  47  ii  11  123  iii  19  167  iV  13  30 Note: "-"= no data available. Abbreviations: gc, gastric cancer; Tcga, The cancer genome atlas. Figure S1 clustering of samples to detect outliers.
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Co-expression network analysis identified CDH11 Figure S2 PPi network of genes in the purple module. Notes: The color intensity of node was correlation. weighted (positive in red and negative in green). The nodes with bold circle are hub genes identified by WGCNA. The edge width was node to the score of PPi based on the sTring database. Abbreviations: PPi, protein-protein interaction; Wgcna, weighted gene co-expression network analysis.
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